Synmosa Biopharma Financials
| 4114 Stock | TWD 34.25 0.15 0.44% |
Synmosa |
Understanding current and past Synmosa Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Synmosa Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Synmosa Biopharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Synmosa Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Synmosa Biopharma. Check Synmosa Biopharma's Beneish M Score to see the likelihood of Synmosa Biopharma's management manipulating its earnings.
Synmosa Biopharma Stock Summary
Synmosa Biopharma competes with GeneFerm Biotechnology, Ruentex Development, Symtek Automation, CTCI Corp, and Information Technology. Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan OTC Exchange |
| ISIN | TW0004114004 |
| Business Address | No 6, Neihu |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.synmosa.com.tw |
| Phone | 886 2 8797 7100 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in Synmosa Biopharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Synmosa Stock, because this is throwing your money away. Analyzing the key information contained in Synmosa Biopharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Synmosa Biopharma Key Financial Ratios
There are many critical financial ratios that Synmosa Biopharma's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Synmosa Biopharma reports annually and quarterly.| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 | |||
| Target Price | 50.0 | |||
| Number Of Employees | 16 | |||
| Beta | 0.34 |
Synmosa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Synmosa Biopharma's current stock value. Our valuation model uses many indicators to compare Synmosa Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Synmosa Biopharma competition to find correlations between indicators driving Synmosa Biopharma's intrinsic value. More Info.Synmosa Biopharma is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.25 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Synmosa Biopharma is roughly 4.01 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Synmosa Biopharma's earnings, one of the primary drivers of an investment's value.Synmosa Biopharma Systematic Risk
Synmosa Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Synmosa Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Synmosa Biopharma correlated with the market. If Beta is less than 0 Synmosa Biopharma generally moves in the opposite direction as compared to the market. If Synmosa Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Synmosa Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Synmosa Biopharma is generally in the same direction as the market. If Beta > 1 Synmosa Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Synmosa Biopharma December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Synmosa Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Synmosa Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Synmosa Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Synmosa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Synmosa Biopharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.37) | |||
| Maximum Drawdown | 5.33 | |||
| Value At Risk | (1.15) | |||
| Potential Upside | 0.7968 |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.